CFRX: DSMB Recommends DISRUPT Study be Stopped for Futility…
Bautz: By David Bautz, PhD
NASDAQ:CFRX
READ THE FULL CFRX RESEARCH REPORT
Nasdaq Turns Positive; Morgan Stanley Posts Weak Q2 Earnings
U.S. stocks pared losses toward the end of trading, with the Nasdaq Composite turning higher on Thursday.
Why U.S. Stocks Are Trading Lower Following Producer Inflation Data
U.S. stocks traded lower this morning, following the release of economic reports on initial jobless claims and producer prices
SVB Leerink Downgrades ContraFect to Market Perform, Lowers Price Target to $1
SVB Leerink analyst Roanna Ruiz downgrades ContraFect (NASDAQ:CFRX) from Outperform to Market Perform and lowers the price target from $9 to $1.
Why Is Ericsson Down By 9%? 22 Stocks Moving In Thursday’s Pre-Market Session
Gainers
Allena Pharmaceuticals, Inc. (NASDAQ: ALNA) rose 22.1% to $0.2050 in pre-market trading. Allena Pharmaceuticals disclosed a new meeting date and new record date for special meeting to approve reverse stock split.
Cantor Fitzgerald Downgrades ContraFect to Neutral, Lowers Price Target to $1
Cantor Fitzgerald analyst Louise Chen downgrades ContraFect (NASDAQ:CFRX) from Overweight to Neutral and lowers the price target from $15 to $1.
ContraFect Shares Plummet After Data Safety Monitoring Board Stops Late-Stage Aureus Bacteremia Study
The Data Safety Monitoring Board (DSMB) has recommended that ContraFect’s (NASDAQ: CFRX) on going DISRUPT trial be stopped because the conditional power of the study was below the pre-specified threshold for futility.